Sotera Health CoSHC

時価総額

$46.4億

PER

医療向け滅菌と試験・助言サービスの最大手。ガンマ/EO/Eビームなどの滅菌と微生物・分析検査を展開。ワーバーグ・ピンカスとGTCRが約43.4%出資、2020年11月にIPO。米国中心に50カ国超で展開。

	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income (loss)	117	-234	51	44
Depreciation	64	64	77	84
Amortization of intangible assets	87	82	81	79
Loss on refinancing of debt	-	-	-	-24
Impairment of investment in unconsolidated affiliate	-	10	-	-
Deferred income taxes	-4	-74	3	9
Share-based compensation expense	14	21	32	37
Accretion expense	2	2	2	3
Unrealized foreign exchange (gain) loss	-1	4	-6	18
Unrealized loss (gain) on derivatives not designated as hedging instruments	-	-3	2	-2
Amortization of debt issuance costs	6	6	9	7
Other	13	7	5	5
Accounts receivable	16	13	22	-2
Inventories	20	-14	10	5
Other current assets	4	6	-4	-4
Accounts payable	20	1	-5	-7
Accrued liabilities	2	21	4	7
Litigation settlement	-	-	-35	35
Income taxes payable / receivable, net	10	-12	1	1
Other liabilities	-0	0	-2	-4
Other long-term assets	4	5	0	7
Net cash provided by (used in) operating activities	282	278	-148	224
Purchases of property, plant and equipment	102	182	215	179
Other investing activities	1	-0	-0	-0
Net cash used in investing activities	-160	-182	-215	-179
Proceeds from Issuance of Long-Term Debt	-	200	500	2,259
Payment of revolving credit facility	-	-	200	-
Payments of debt issuance costs and debt discount	-	-	-	32
Payments of long-term borrowings	100	-	3	2,264
Buyout of leased facility	-	-	-	7
Shares withheld for employee taxes on equity awards	1	0	4	4
Other financing activities	-1	-2	-2	-2
Net cash (used in) provided by financing activities	-117	198	266	-51
Effect of exchange rate changes on cash and cash equivalents	0	-4	2	-17
Net (decrease) increase in cash and cash equivalents, including restricted cash	4	289	-95	-23
Cash paid during the period for interest	59	76	174	180
Income Taxes Paid, Net	52	75	50	66
Capital Expenditures Incurred but Not yet Paid	15	16	17	10